



























- 120) Soucie JM, Siwak EB, Hooper WC, et al.; Universal Data Collection Project Working Group. Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation. *Transfusion* 2004; **44**: 1179-85.
- 121) Brojer E, Grabarczyk P, Łopaciuk S, et al. Prevalence of human parvovirus B19 DNA and IgG/IgM antibodies in Polish haemophilia patients. *Vox Sang* 1999; **77**: 107.
- 122) Canales MA, Pinilla J, Mateos P. Human parvovirus B19 antibodies are less frequent among patients treated with factor IX concentrate inactivated by ultrafiltration: a report from a single Spanish institution. *Vox Sang* 1998; **74**: 260-1.
- 123) Mauser-Bunschoten EP, Zaaier HL, van Drimmelen AA. High prevalence of Parvovirus B19 IgG antibodies among Dutch hemophilia patients. *Vox Sang* 1998; **74**: 225-7.
- 124) Aguilar Franco C, Lucía Cuesta JF, Ferrer Torres J, Omeñaca Teres M. Parvovirus B19 infection in patients with congenital blood coagulation disorders. *Med Clin (Barc)* 1997; **108**: 641-6. Erratum in: *Med Clin (Barc)* 1997; **109**: 5 [In Spanish].
- 125) Ragni MV, Koch WC, Jordan JA. Parvovirus B19 infection in patients with hemophilia. *Transfusion* 1996; **36**: 238-41.
- 126) Zakrzewska K, Azzi A, De Biasi E, et al. Persistence of parvovirus B19 DNA in synovium of patients with haemophilic arthritis. *J Med Virol* 2001; **65**: 402-7.
- 127) Bartolomei Corsi O, Azzi A, Morfini M, et al. Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates. *J Med Virol* 1988; **25**: 165-70.
- 128) Manning A, Willey SJ, Bell JE, Simmonds P. Comparison of tissue distribution, persistence, and molecular epidemiology of parvovirus B19 and novel human parvoviruses PARV4 and human bocavirus. *J Infect Dis* 2007; **195**: 1345-52.
- 129) Jones MS, Kapoor A, Lukashov VV, et al. New DNA viruses identified in patients with acute viral infection syndrome. *J Virol* 2005; **79**: 8230-6.
- 130) Fryer JF, Delwart E, Hecht FM, et al. Frequent detection of the parvoviruses, PARV4 and PARV5, in plasma from blood donors and symptomatic individuals. *Transfusion* 2007; **47**: 1054-61.
- 131) Simmonds P, Douglas J, Bestetti G, et al. A third genotype of the human parvovirus PARV4 in sub-Saharan Africa. *J Gen Virol* 2008; **89**: 2299-302.
- 132) Drexler JF, Reber U, Muth D, et al. Human parvovirus 4 in nasal and fecal specimens from children, Ghana. *Emerg Infect Dis* 2012; **18**: 1650-3.
- 133) Ma YY, Guo Y, Zhao X, et al. Human parvovirus PARV4 in plasma pools of Chinese origin. *Vox Sang* 2012; **103**: 183-5.
- 134) Fryer JF, Hubbard AR, Baylis SA. Human parvovirus PARV4 in clotting factor VIII concentrates. *Vox Sang* 2007; **93**: 341-7.
- 135) Schneider B, Fryer JF, Oldenburg J, et al. Frequency of contamination of coagulation factor concentrates with novel human parvovirus PARV4. *Haemophilia* 2008; **14**: 978-86.
- 136) Eis-Hübinger AM, Drexler JF, Reber U, et al. Absence of detection of novel human parvoviruses in German plasma donations. *Transfusion* 2010; **50**: 266-7.
- 137) Baylis SA, Tuke PW, Miyagawa E, Blümel J. Studies on the inactivation of human parvovirus 4. *Transfusion* 2013; **53**: 2585-92.
- 138) Fryer JF, Lucas SB, Padley D, Baylis SA. Parvoviruses PARV4/5 in hepatitis C virus-infected persons. *Emerg Infect Dis* 2007; **13**: 175-6.
- 139) Simmonds P, Manning A, Kenneil R, et al. Parenteral transmission of the novel human parvovirus PARV4. *Emerg Infect Dis* 2007; **13**: 1386-8.
- 140) Longhi E, Bestetti G, Acquaviva V, et al. Human parvovirus 4 in the bone marrow of Italian patients with AIDS. *AIDS* 2007; **21**: 1481-3.
- 141) Lurcharchaiwong W, Chieochansin T, Payungporn S, et al. Parvovirus 4 (PARV4) in serum of intravenous drug users and blood donors. *Infection* 2008; **36**: 488-91.
- 142) Fryer JF, Kapoor A, Minor PD, et al. Novel parvovirus and related variant in human plasma. *Emerg Infect Dis* 2006; **12**: 151-4.
- 143) Vallerini D, Barozzi P, Quadrelli C, et al. Parvoviruses in blood donors and transplant patients, Italy. *Emerg Infect Dis* 2008; **14**: 185-6.
- 144) Botto S, Bergallo M, Sidoti F, et al. Detection of PARV4, genotypes 1 and 2, in healthy and pathological clinical specimens. *New Microbiol* 2009; **32**: 189-92.
- 145) Servant-Delmas A, Laperche S, Mercier M, et al. Human parvovirus 4 in recipients of cellular products and in blood donors: epidemiologic similarity with B19 parvovirus. *Transfusion* 2009; **49**: 1771-3.
- 146) Tuke PW, Parry RP, Appleton H. Parvovirus PARV4 visualization and detection. *J Gen Virol* 2010; **91**: 541-4.
- 147) Panning M, Kobbe R, Vollbach S, et al. Novel human parvovirus 4 genotype 3 in infants, Ghana. *Emerg Infect Dis* 2010; **16**: 1143-6.
- 148) Touinssi M, Brisbarre N, Picard C, et al. Parvovirus 4 in blood donors, France. *Emerg Infect Dis* 2010; **16**: 165-6.
- 149) Touinssi M, Reynaud-Gaubert M, Gomez C, et al. Parvovirus 4 in French in-patients: a study of hemodialysis and lung transplant cohorts. *J Med Virol* 2011; **83**: 717-20.
- 150) Maple PA, Beard S, Parry RP, et al. Testing UK blood donors for exposure to human parvovirus 4 using a time-resolved fluorescence immunoassay to screen sera and Western blot to confirm reactive samples. *Transfusion* 2013; **53**: 2575-84.
- 151) Sharp CP, Lail A, Donfield S, et al. Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates. *Transfusion* 2012; **52**: 1482-9.
- 152) Allander T, Tammi MT, Eriksson M, et al. Cloning of a human parvovirus by molecular screening of respiratory tract samples. *Proc Natl Acad Sci USA* 2005; **102**: 12891-96.
- 153) Jartti T, Hedman K, Jartti L, et al. Human bocavirus-the first 5 years. *Rev Med Virol* 2012; **22**: 46-64.
- 154) Norja P, Hedman L, Kantola K, et al. Occurrence of human bocaviruses and parvovirus 4 in solid tissues. *J Med Virol* 2012; **8**: 1267-73.
- 155) Kantola K, Hedman L, Arthur J, et al. Seroepidemiology of human bocaviruses 1-4. *J Infect Dis* 2011; **204**: 1403-12.
- 156) Di Minno G, Canaro M, Ironside JW, et al. Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice. *Haematologica* 2013; **98**: 1495-8.
- 157) Groeneveld K, van der Noordaa J. Blood products and parvovirus B19. *Neth J Med* 2003; **61**: 154-6.
- 158) AABB Special Issue: Emerging Infectious Disease Agents and their Potential Threat to Transfusion Safety. Human Parvovirus B19. *Transfusion* 2009; **49**: 107S-9S.

---

Arrived: 8 July 2014 - Revision accepted: 9 October 2014

**Correspondence:** Giancarlo M. Liumbruno  
 Italian National Blood Centre  
 Via Giano della Bella 27  
 00162 Rome, Italy  
 e-mail: giancarlo@liumbruno.it

---